GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Diva Laboratories Ltd (ROCO:4153) » Definitions » Return-on-Tangible-Equity

Diva Laboratories (ROCO:4153) Return-on-Tangible-Equity : 5.89% (As of Sep. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Diva Laboratories Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Diva Laboratories's annualized net income for the quarter that ended in Sep. 2024 was NT$60.3 Mil. Diva Laboratories's average shareholder tangible equity for the quarter that ended in Sep. 2024 was NT$1,023.7 Mil. Therefore, Diva Laboratories's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2024 was 5.89%.

The historical rank and industry rank for Diva Laboratories's Return-on-Tangible-Equity or its related term are showing as below:

ROCO:4153' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -32.97   Med: 4.95   Max: 29.53
Current: 6.97

During the past 13 years, Diva Laboratories's highest Return-on-Tangible-Equity was 29.53%. The lowest was -32.97%. And the median was 4.95%.

ROCO:4153's Return-on-Tangible-Equity is ranked better than
61.78% of 191 companies
in the Medical Diagnostics & Research industry
Industry Median: -0.45 vs ROCO:4153: 6.97

Diva Laboratories Return-on-Tangible-Equity Historical Data

The historical data trend for Diva Laboratories's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diva Laboratories Return-on-Tangible-Equity Chart

Diva Laboratories Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.35 4.91 1.66 2.24 4.99

Diva Laboratories Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24 Jun24 Sep24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.77 7.76 9.77 12.40 5.89

Competitive Comparison of Diva Laboratories's Return-on-Tangible-Equity

For the Diagnostics & Research subindustry, Diva Laboratories's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diva Laboratories's Return-on-Tangible-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Diva Laboratories's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Diva Laboratories's Return-on-Tangible-Equity falls into.



Diva Laboratories Return-on-Tangible-Equity Calculation

Diva Laboratories's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2022 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=49.661/( (976.828+1014.87 )/ 2 )
=49.661/995.849
=4.99 %

Diva Laboratories's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=60.296/( (1017.313+1030.071)/ 2 )
=60.296/1023.692
=5.89 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Diva Laboratories  (ROCO:4153) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Diva Laboratories Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Diva Laboratories's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Diva Laboratories Business Description

Traded in Other Exchanges
N/A
Address
Zhongshan Road, 9F, No. 351, Sector 2, Zhonghe District, New Taipei City, TWN, 235
Diva Laboratories Ltd is a Taiwan-based company that engages in the sale, manufacturing, and development of medical equipment and computer-related devices. It offers endo/surgical displays; color displays for radiology and medical imaging services; touch displays; and original design manufacturing and original equipment manufacturing solutions.

Diva Laboratories Headlines

No Headlines